Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

US FDA accepts the NDA for Motif Bio’s iclaprim for ABSSSI treatment

pharmaceutical-technologyAugust 17, 2018

Tag: ABSSSI , FDA

PharmaSources Customer Service